Rubicon Research

RUBICONPharmaceuticals
640.20+0.00 (+0.00%)
As on 01 Dec 2025, 04:21 pmMarket Closed

Fundamental Score

...

Rubicon Research Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Excellent

Return on Equity

29.02%
Excellent

Return on Capital Employed

26.16%
Excellent

Operating Profit Margin (5Y)

15.50%
Poor

Dividend Yield

0.00%

Valuation Metrics

Poor

Price to Earnings

68.60x

Market Capitalization

10.55K (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

56.18%
Excellent

YoY Quarterly Sales Growth

39.19%
Excellent

Sales Growth (5Y)

37.32%
Poor

EPS Growth (5Y)

-37.89%
Excellent

Profit Growth (5Y)

22.95%

Financial Health

Poor

Debt to Equity

0.88x
Excellent

Interest Coverage

6.29x
Poor

Free Cash Flow (5Y)

-189.53 (Cr)

Ownership Structure

Good

Promoter Holding

59.99%
Average

FII Holding

9.38%
Good

DII Holding

10.54%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Mid-cap
Balance of growth potential and stability.
59.99%
Promoter Holding
10.55K (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of RUBICON across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Strong Return on Equity (29.02%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (26.16%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Strong Operating Margins (15.50%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.

Robust Profit Growth (56.18%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Strong Revenue Growth (39.19%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Consistent Growth Track Record (37.32% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.

Strong Profit Growth Track Record (22.95% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Strong Interest Coverage (6.29x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Balanced Promoter Holding (59.99%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

6 factors identified

Premium Valuation Risk (P/E: 68.60x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

Weak Earnings Growth (-37.89% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.

Negative Free Cash Flow (₹-189.53 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Very High P/E Ratio

Observation: Significant overvaluation risk present.

Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.

Financial Statements

Comprehensive financial data for Rubicon Research

About RUBICON

Company Details

Symbol:RUBICON
Industry:Pharmaceuticals
Sector:N/A
Website:N/A

RUBICON Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)29.02%
Return on Capital Employed26.16%
Operating Profit Margin (5Y)15.50%
Debt to Equity Ratio0.88
Interest Coverage Ratio6.29

Growth & Valuation

Sales Growth (5Y)37.32%
Profit Growth (5Y)22.95%
EPS Growth (5Y)-37.89%
YoY Quarterly Profit Growth56.18%
YoY Quarterly Sales Growth39.19%

Frequently Asked Questions

What is the current price of Rubicon Research (RUBICON)?

As of 01 Dec 2025, 04:21 pm IST, Rubicon Research (RUBICON) is currently trading at ₹640.20. The stock has a market capitalization of ₹10.55K (Cr).

Is RUBICON share price Overvalued or Undervalued?

RUBICON is currently trading at a P/E ratio of 68.60x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.

What factors affect the Rubicon Research share price?

Key factors influencing RUBICON's price include its quarterly earnings growth (Sales Growth: 39.19%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Rubicon Research a good stock for long-term investment?

Rubicon Research shows a 5-year Profit Growth of 22.95% and an ROE of 29.02%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.88 before investing.

How does Rubicon Research compare with its industry peers?

Rubicon Research competes with major peers in the Pharmaceuticals. Investors should compare RUBICON's P/E of 68.60x and ROE of 29.02% against the industry averages to determine its competitive standing.

What is the P/E ratio of RUBICON and what does it mean?

RUBICON has a P/E ratio of 68.60x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹69 for every ₹1 of annual earnings.

How is RUBICON performing according to Bull Run's analysis?

RUBICON has a Bull Run fundamental score of 44.2/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does RUBICON belong to?

RUBICON operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Rubicon Research.

What is Return on Equity (ROE) and why is it important for RUBICON?

RUBICON has an ROE of 29.02%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Rubicon Research generates profits from shareholders' equity.

How is RUBICON's debt-to-equity ratio and what does it indicate?

RUBICON has a debt-to-equity ratio of 0.88, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.

What is RUBICON's dividend yield and is it a good dividend stock?

RUBICON offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has RUBICON grown over the past 5 years?

RUBICON has achieved 5-year growth rates of: Sales Growth 37.32%, Profit Growth 22.95%, and EPS Growth -37.89%.

What is the promoter holding in RUBICON and why does it matter?

Promoters hold 59.99% of RUBICON shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is RUBICON's market capitalization category?

RUBICON has a market capitalization of ₹10547 crores, placing it in the Mid-cap category.

How volatile is RUBICON stock?

RUBICON has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for RUBICON?

RUBICON has a 52-week high of ₹N/A and low of ₹N/A.

What is RUBICON's operating profit margin trend?

RUBICON has a 5-year average Operating Profit Margin (OPM) of 15.50%, indicating the company's operational efficiency.

How is RUBICON's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 39.19% and YoY Profit Growth of 56.18%.

What is the institutional holding pattern in RUBICON?

RUBICON has FII holding of 9.38% and DII holding of 10.54%. Significant institutional holding often suggests professional confidence in the stock.